Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) were up 2.6% during mid-day trading on Monday . The company traded as high as $9.06 and last traded at $8.76, with a volume of 54,724 shares trading hands. The stock had previously closed at $8.54.

Separately, Zacks Investment Research upgraded CoLucid Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.

The company’s market cap is $133.56 million. The stock’s 50 day moving average price is $8.84 and its 200-day moving average price is $7.08.

CoLucid Pharmaceuticals (NASDAQ:CLCD) last posted its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by $0.22. Equities research analysts anticipate that CoLucid Pharmaceuticals Inc. will post ($4.01) earnings per share for the current year.

In other CoLucid Pharmaceuticals news, major shareholder Domain Partners Vi, L.P. sold 153,028 shares of CoLucid Pharmaceuticals stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $8.45, for a total value of $1,293,086.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.